SCHEMBL5526189

SCHEMBL5526189

NC(=O)OCCCCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28331698 0.98 LMNA (0.42)
SCHEMBL20553423 0.98 LMNA (0.42)
SCHEMBL28266398 0.98 LMNA (0.42)
SCHEMBL29098538 0.98 LMNA (0.42)
SCHEMBL28331697 0.98 LMNA (0.42)
SCHEMBL2678528 0.92
Carbamic Acid SCHEMBL2823803 0.88 LMNA (0.47)
SCHEMBL2746597 0.87 TSHR (0.52)
SCHEMBL2746089 0.84 TSHR (0.50)
SCHEMBL2059697 0.84 TSHR (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113402523-B Targeted mast cell MrgX2 small-molecule fluorescent probe and preparation method and application thereof 西安交通大学 2022-07-12 CN claimed
CN-113402523-A Targeted mast cell MrgX2 small-molecule fluorescent probe and preparation method and application thereof 西安交通大学 2021-09-17 CN claimed
EP-4731309-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2026-04-29 EP disclosed
US-12404285-B2 KRAS G12D proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2025-09-02 US disclosed
US-20250051364-A1 KRAS G12D Proteolysis Targeting Chimeras PAQ Therapeutics Inc. (US) 2025-02-13 US disclosed
WO-2024263586-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS PAQ Therapeutics Inc. (US) 2024-12-26 WO disclosed
US-20240247000-A1 KRAS G12D Proteolysis Targeting Chimeras PAQ Therapeutics Inc. (US) 2024-07-25 US disclosed
EP-4398911-A2 INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS Memorial Sloan Kettering Cancer Center (US) 2024-07-17 EP disclosed
EP-4392420-A1 HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME BIOFRONT LTD (KY) 2024-07-03 EP disclosed
CN-117362239-B Luminol etherified derivative and preparation method and application thereof 广州中医药大学(广州中医药研究院) 2024-06-07 CN disclosed
CN-112079866-B ALK protein regulator and anti-tumor application thereof 上海科技大学 2024-05-31 CN disclosed
CN-110770243-A Rapamycin analogs as MTOR inhibitors 锐新医药公司 2020-02-07 CN disclosed
CN-110615779-A Process for preparing lenalidomide derivatives 上海科技大学 2019-12-27 CN disclosed
CN-110357889-A Protein degradation target compound, its antitumor application thereof, wherein mesosome and intermediate application 上海科技大学 2019-10-22 CN disclosed
CN-109912655-A Alk protein degradation agent and its antitumor application thereof 上海科技大学 2019-06-21 CN disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
CN-1374863-A Bicyclic antagonists selective for the alpha beta integrin WHAE S INC (US) 2002-10-16 CN disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed